top of page

BioCryst aims to leverage its commercial success to accelerate a robust pipeline based on structure-guided drug design

CEO Jon Stonehouse describes how making it across the finish line with Orladeyo has put BioCryst in a position after may decades of drug development to ramp R&D while partnering larger indications.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page